| Abstract: | Objective To investigate the efficacy and safety of the second-generation argon plasma coagulation (VIO APC) in ablation of Barrett's esophagus. Methods Eighteen patients with Barrett's esophagus (12 males, median age of 55 years, median length of 2.1 cm,1 low-grade dysplasia, 13 cases of short segment Barrett's esophagus) received VIO APC, which was performed at a power setting of 40W and argon gas flow at 1. 5-2. 0 L/min, "forced" mode, in 1-3 sessions (mean 1.3). All the patients received treatment with high-dose proton pump inhibitors. The main complaints before ablation were upper abdominal pain in 12 patients (66%), sour regurgitation in 14 patients (77%), and dysphagia or odynophagia in 7 patients (38%). Two patients (11%) had esophageal hiatal hernia. Results The percentage of patients in whom ablation was endoscopically achieved proximal to the gastroesophageal junction was 77. 8%(14/18), and histologically achieved in 66. 7% (12/18). Berried glands were observed in 2 patients who had achieved endoscopic ablation, the areas of Barrett's mucosa were reduced by more than 60% in the other 4 patients. After treatment, 4 patients had transient retrosternal pain and 3 patients had mild epigastric discomfort. One patient had small amounts of hemorrhage during the process, and it ceased after norepinephrine and thrombosin were administered through endoscope biopsy channel. No esophageal stricture or other severe adverse events was observed. During 11.8 (4-15) months' follow-up, the patients who had achieved the complete ablation had no evidence of relapse of Barrett's esophagus. Conclusion VIO APC with a relatively low power setting can effectively ablate the Barrett's mucosa with special intestinal metaplasia when standard APC has been done. No severe adverse events were observed. Long-term follow-up is needed to assess cancer prevention and the durability of the neo-squamous epithelium. |
